Total submissions: 9
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Blueprint Genetics | RCV000208047 | SCV000263951 | uncertain significance | Hemochromatosis type 1 | 2015-11-18 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000557367 | SCV000633733 | uncertain significance | Hereditary hemochromatosis | 2025-01-27 | criteria provided, single submitter | clinical testing | This sequence change replaces glutamic acid, which is acidic and polar, with glutamine, which is neutral and polar, at codon 168 of the HFE protein (p.Glu168Gln). This variant is present in population databases (rs146519482, gnomAD 0.1%), and has an allele count higher than expected for a pathogenic variant. This missense change has been observed in individual(s) with hemochromatosis (PMID: 10953950, 12681966, 15025725, 15477198, 19214108, 19787796). ClinVar contains an entry for this variant (Variation ID: 222651). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is not expected to disrupt HFE protein function with a negative predictive value of 80%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Center for Precision Medicine, |
RCV000208047 | SCV000889988 | uncertain significance | Hemochromatosis type 1 | 2018-03-16 | criteria provided, single submitter | research | |
Ce |
RCV000998548 | SCV001154677 | uncertain significance | not provided | 2023-03-01 | criteria provided, single submitter | clinical testing | HFE: PM2, BP4 |
Illumina Laboratory Services, |
RCV000208047 | SCV001319374 | uncertain significance | Hemochromatosis type 1 | 2017-04-27 | criteria provided, single submitter | clinical testing | This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). Publications were found based on this search. However, the evidence from the literature, in combination with allele frequency data from public databases where available, was not sufficient to rule this variant in or out of causing disease. Therefore, this variant is classified as a variant of unknown significance. |
Gene |
RCV000998548 | SCV001804916 | uncertain significance | not provided | 2024-07-18 | criteria provided, single submitter | clinical testing | Identified in individuals with hereditary hemochromatosis; however, all reported individuals also harbored other variants in the HFE gene and it remains unclear whether this variant is sufficient to cause disease (PMID: 10953950, 12537660, 12681966, 15477198, 19214108, 19787796); Identified in a patient with hyperferritinemia and analyses suggested this variant was in cis with the p.(His63Asp) variant (PMID: 29084376); In silico analysis indicates that this missense variant does not alter protein structure/function; This variant is associated with the following publications: (PMID: 12870733, 12681966, 15477198, 12537660, 12952143, 15025725, 19214108, 19787796, 29590070, 34426522, 10953950, 19759876, 29084376) |
Fulgent Genetics, |
RCV002485360 | SCV002776008 | uncertain significance | Variegate porphyria; Microvascular complications of diabetes, susceptibility to, 7; Alzheimer disease type 1; Hemochromatosis type 1; TRANSFERRIN SERUM LEVEL QUANTITATIVE TRAIT LOCUS 2; Familial porphyria cutanea tarda | 2021-11-22 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV000208047 | SCV003801493 | uncertain significance | Hemochromatosis type 1 | 2023-02-08 | criteria provided, single submitter | clinical testing | |
Mayo Clinic Laboratories, |
RCV000998548 | SCV004227200 | uncertain significance | not provided | 2022-11-29 | criteria provided, single submitter | clinical testing | BP4 |